A phase 3, multicenter, double blind, placebo-controlled, randomized withdrawal trial to evaluate the efficacy, safety, and pharmacokinetics of deucravacitinib in children and adolescents from 5 to less than 18 years of age with active juvenile psoriatic arthritis

• Protocol code: IM011-1071
• EudraCT code: No aplica
• Research group: Rheumatology
• Service: Rheumatology
• Principal investigator:  Lopez Corbeto, Mireia
• Pathology: Símptomes, signes i troballes anormals clíniques i de laboratori, no classificades enlloc més
• Phase: Fase III